NaseemAJaffraniMDFACC, FSCAI

Cardiology • Alexandria, LA

Cardiac Electrophysiology, Interventional Cardiology

Alexandria Cardiology Clinic

Join to view full profile

Dr. Jaffrani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jaffrani's full profile

Already have an account?

Office
501 Medical Center Dr
Suite 250
Alexandria, LA 71301
Phone+1 318-473-4613

Fax+1 318-445-7129

Education & Training

Chicago Medical School/Rosalind Franklin University of Medicine & ScienceFellowship, Cardiovascular Disease, 1997
Chicago Medical School/Rosalind Franklin University of Medicine & ScienceResidency, Internal Medicine, 1994
Chicago Medical School/Rosalind Franklin University of Medicine & ScienceInternship, Internal Medicine, 1991 - 1992
Sind Medical CollegeClass of 1989

Certifications & Licensure

LA State Medical License 1997 - 2026
SC State Medical License 2015 - 2015
AZ State Medical License 1997 - 2000
IL State Medical License 1991 - 1999
WI State Medical License 1993 - 1995
American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

Fellow (FACC) American College of Cardiology

Clinical Trials

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure Start of enrollment: 2012 Jul 01
Completed
Phase 3
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19 Start of enrollment: 2020 Oct 09
Completed
Phase 2
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Start of enrollment: 2021 Nov 23
ACTIVE_NOT_RECRUITING
PHASE3
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors Start of enrollment: 2020 Jan 27
Active, not recruiting
Not Applicable
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen Start of enrollment: 2023 Mar 13
COMPLETED
PHASE2
Roles: Contact
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Start of enrollment: 2024 Apr 30
RECRUITING
PHASE3
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Start of enrollment: 2024 Mar 05
RECRUITING
PHASE3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. Start of enrollment: 2023 Mar 09
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

25 citations
An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease.
Michael J Koren, Fatima Rodriguez, Cara East, Peter P Toth, Veena Watwe
Journal of the American College of Cardiology. 2024-05-21
8 citations
Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function.
Alex D Hakim, Mustafa Awili, Hollis R O'Neal, Omar Siddiqi, Naseem Jaffrani
Clinical and Experimental Immunology. 2023-10-13
24 citations
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a po...
Subodh Verma, Nitish K. Dhingra, Javed Butler, Stefan D. Anker, João Pedro Ferreira
The Lancet. Diabetes & Endocrinology. 2021-11-30

Professional Memberships

American College of Cardiology - ACC
Fellow
Society of Coronary Angiography & Intervention
Fellow

Other Languages

Hindi, Urdu